ArticleBlood advances2025
PRIDE-FTG advances academic careers of underrepresented early-stage investigators performing blood disorders research.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
abstractDespite improvements in the diversity of the US biomedical research workforce, individuals from different racial/ethnic groups remain underrepresented. Even though mentoring is critical for career advancement, underrepresented faculty have limited opportunities. Therefore, we evaluated a multipronged mentoring approach for early-stage underrepresented faculty trained in the Programs to Increase Diversity Among Individuals Engaged in Health-Related Research-Functional and Translational Genomics of Blood Disorders (PRIDE-FTG). The selection process involved a rigorous review of applications, considering factors such as academic potential, research interests, and commitment to diversity in biomedical research. This yearlong training experience includes 2 summer institutes consisting of lectures, grant-writing workshops, and laboratory practicums. In addition, a mentoring committee, comprised of research, career development, and peer mentors, was established. The National Coordination Core collected program evaluations, grants, publications, and academic promotion data. Since 2007, PRIDE-FTG has trained 114 investigators, including 94 Black/African American investigators and 87 assistant professors; 65 mentees (57%) conducted research related to sickle cell disease. The primary outcome metric for PRIDE-FTG is the submission of an extramural National Institutes of Health or equivalent grant within 2 years of training completion. Notably, 70% of 90 mentees achieved this metric and 44.4% was funded as principal investigators. Finally, 55 mentees were promoted to higher academic ranks, and 90 mentees published 1465 peer-reviewed manuscripts. Our data demonstrated the long-term impact of PRIDE-FTG training on the career advancement of early-stage underrepresented investigators. The success of this structured, mentored training program instills a sense of optimism about the future of diversity in our nation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.